These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26328445)

  • 1. Cationic Nanoemulsions as a Gene Delivery System: Proof of Concept in the Mucopolysaccharidosis I Murine Model.
    Fraga M; de Carvalho TG; Diel Dda S; Kretzmann Filho NA; Teixeira HF; Matte U
    J Nanosci Nanotechnol; 2015 Jan; 15(1):810-6. PubMed ID: 26328445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model.
    Fraga M; Bruxel F; Diel D; de Carvalho TG; Perez CA; Magalhães-Paniago R; Malachias Â; Oliveira MC; Matte U; Teixeira HF
    J Control Release; 2015 Jul; 209():37-46. PubMed ID: 25886705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers.
    Schuh RS; de Carvalho TG; Giugliani R; Matte U; Baldo G; Teixeira HF
    Eur J Pharm Biopharm; 2018 Jan; 122():158-166. PubMed ID: 29122734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy.
    Schuh RS; Bidone J; Poletto E; Pinheiro CV; Pasqualim G; de Carvalho TG; Farinon M; da Silva Diel D; Xavier RM; Baldo G; Matte U; Teixeira HF
    Pharm Res; 2018 Sep; 35(11):221. PubMed ID: 30259180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice.
    Bidone J; Schuh RS; Farinon M; Poletto É; Pasqualim G; de Oliveira PG; Fraga M; Xavier RM; Baldo G; Teixeira HF; Matte U
    Int J Pharm; 2018 Sep; 548(1):151-158. PubMed ID: 29940298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model.
    Fraga M; de Carvalho TG; Bidone J; Schuh RS; Matte U; Teixeira HF
    Int J Nanomedicine; 2017; 12():2061-2067. PubMed ID: 28352175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy of Mucopolysaccharidosis Type I Mice: Repeated Administrations and Safety Assessment of pIDUA/Nanoemulsion Complexes.
    Fraga M; Schuh RS; Poletto É; de Carvalho TG; França RT; Pinheiro CV; Baldo G; Giugliani R; Teixeira HF; Matte U
    Curr Gene Ther; 2021; 21(5):464-471. PubMed ID: 33573568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical properties of cationic nanoemulsions and liposomes obtained by microfluidization complexed with a single plasmid or along with an oligonucleotide: Implications for CRISPR/Cas technology.
    Schuh RS; Poletto É; Fachel FNS; Matte U; Baldo G; Teixeira HF
    J Colloid Interface Sci; 2018 Nov; 530():243-255. PubMed ID: 29982016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of phospholipid composition on cationic emulsions/DNA complexes: physicochemical properties, cytotoxicity, and transfection on Hep G2 cells.
    Fraga M; Bruxel F; Lagranha VL; Teixeira HF; Matte U
    Int J Nanomedicine; 2011; 6():2213-20. PubMed ID: 22114484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system.
    Schuh RS; Poletto É; Pasqualim G; Tavares AMV; Meyer FS; Gonzalez EA; Giugliani R; Matte U; Teixeira HF; Baldo G
    J Control Release; 2018 Oct; 288():23-33. PubMed ID: 30170069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
    Di Domenico C; Di Napoli D; Gonzalez Y Reyero E; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2006 Nov; 17(11):1112-21. PubMed ID: 17044753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of alginate microcapsules containing cells overexpressing α-l-iduronidase using Box-Behnken design.
    Diel D; Lagranha VL; Schuh RS; Bruxel F; Matte U; Teixeira HF
    Eur J Pharm Sci; 2018 Jan; 111():29-37. PubMed ID: 28882767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts.
    de Carvalho TG; Schuh R; Pasqualim G; Pellenz FM; Filippi-Chiela EC; Giugliani R; Baldo G; Matte U
    Gene; 2018 Dec; 678():33-37. PubMed ID: 30081189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells.
    Baldo G; Quoos Mayer F; Burin M; Carrillo-Farga J; Matte U; Giugliani R
    Cells Tissues Organs; 2012; 195(4):323-9. PubMed ID: 21778683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
    Ou L; Przybilla MJ; Koniar B; Whitley CB
    Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts.
    Huang MM; Wong A; Yu X; Kakkis E; Kohn DB
    Gene Ther; 1997 Nov; 4(11):1150-9. PubMed ID: 9425437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.
    Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR
    Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonviral in vivo gene transfer in the mucopolysaccharidosis I murine model.
    Camassola M; Braga LM; Delgado-Cañedo A; Dalberto TP; Matte U; Burin M; Giugliani R; Nardi NB
    J Inherit Metab Dis; 2005; 28(6):1035-43. PubMed ID: 16435197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.